Core Viewpoint - The event "2025 Zhejiang Business Attackers Sword Contest" highlighted the integration of AI technology in the healthcare sector, with Di'an Diagnostics recognized for its innovative contributions and leadership in this field [1][2]. Group 1: Company Achievements - Di'an Diagnostics was awarded the title of "2025 Zhejiang Business 'AI+' TOP100," and its rotating president, Shi Yupeng, received the "2025 Zhejiang Business 'AI+' Outstanding Leader" award, reflecting the company's commitment to integrating cutting-edge AI technology with medical services [1]. - The company has established a significant presence in the healthcare sector, serving over 22,000 medical institutions and processing more than 200,000 testing samples daily, generating over 600,000 medical diagnostic data points [2]. Group 2: Strategic Initiatives - Di'an Diagnostics is focused on becoming a "technology-driven + data-driven" health big data company, utilizing "AI + big data" as a driving force to build a comprehensive health diagnosis and management industry chain [2]. - The company has developed a chronic myeloid leukemia (CML) patient drug withdrawal prediction model in collaboration with Wuhan Union Hospital, addressing critical issues such as adverse reactions and economic burdens associated with long-term medication [3]. Group 3: Industry Impact - By constructing a "smart medical community," Di'an Diagnostics is enhancing testing capabilities in grassroots medical institutions and promoting tiered diagnosis and treatment [5]. - The company is exploring personalized precision diagnosis and shared medical models, aiming to create a health management ecosystem that encompasses prevention, diagnosis, treatment, and rehabilitation [5]. Group 4: International Expansion - Di'an Diagnostics has begun to expand its services internationally, with the opening of a laboratory in Vietnam in 2024, which has achieved ISO 15189 accreditation, indicating compliance with international quality standards [6]. - The company's pathology AI-assisted diagnostic system has been deployed in 11 hospitals under the IHH Healthcare Berhad group in Malaysia, handling 80% of cervical cancer screenings in the country [6].